Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved avatrombopag for thrombocytopenia in CLD patients scheduled for a procedure

/1 Comment/in /by

 

You might also like
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Obinutuzumab plus chemotherapy FDA approved for follicular lymphoma
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Dasatinib FDA approved in paediatric patients with chronic phase Ph+ CML
FDA approved nilotinib for paediatric patients with newly diagnosed Ph+ CML-CP or Ph+ CML-CP resistant or intolerant to prior TKI
us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious.jpg Nivolumab approved for sorafenib-refractory HCC
Erdafitinib FDA approved for the treatment of metastatic urothelial carcinoma
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Ribociclib FDA label updated to include pre- and perimenopausal women
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Brentuximab vedotin FDA approved for pre-treated primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides
Dacomitinib FDA approved for the first-line treatment of metastatic EGFR-mutated NSCLC
1 reply

Trackbacks & Pingbacks

  1. FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure - MediNews Asia says:
    23rd May 2018 at 11:47 PM

    […] post FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure appeared first on Medical Writer Agency | 香港醫學作家 | MediPR | MediPaper Hong […]

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply